LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
Shweta Urva, Tamer Coşkun, Mei Teng Loh, Yu Du, Melissa K. Thomas, Sirel Gurbuz, Axel Haupt, Charles Benson, Martha Hernandez‐Illas, David A. D’Alessio, Zvonko Miličević
Topics & Concepts
MedicineDulaglutideTolerabilityPlaceboType 2 diabetesInternal medicinePharmacodynamicsExenatidePharmacokineticsDiabetes mellitusGlucagon-like peptide 1 receptorCohortClinical endpointEndocrinologyRandomized controlled trialAgonistAdverse effectReceptorPathologyAlternative medicineDiabetes Treatment and ManagementNeuropeptides and Animal PhysiologyProtein Hydrolysis and Bioactive Peptides